期刊文献+

橄榄苦苷对成骨细胞增殖的影响 被引量:4

Effect of oleuropein on OPG/RANKL mRNA in osteoblasts
在线阅读 下载PDF
导出
摘要 目的探讨橄榄苦苷不同药物浓度及不同作用时间对成骨细胞增殖的影响。方法采用酶消化法原代培养新出生48h内SD大鼠颅骨成骨细胞,药物刺激组加入400、200l、100、50μg/ml橄榄苦苷,另设空白对照组。运用NBT/BCIP试剂盒进行成骨细胞碱性磷酸酶染色鉴定,并采用四甲基偶氮唑蓝法(MTT法)检测应用不同浓度橄榄苦苷及不同作用时间对成骨细胞增殖情况。结果与空白对照组比较,400l、200、100、50μg/m L橄榄苦苷对成骨细胞均具有增殖作用,差异有统计学意义(P<0.05),不同时间点中100μg/m L橄榄苦苷的溶度对成骨细胞的增殖作用最强(P<0.05),作用时间48和72 h后成骨细胞的增殖率及OD值没有明显的差异(P>0.05)。结论橄榄苦苷可以促进成骨细胞的增殖,可能通过增加成骨细胞OPG表达并与成骨细胞膜上雌激素受体结合,促进成骨细胞的增殖来防治骨质疏松,但该机制有待于我们后期实验进一步研究。 Objective To explore the mechanism of oleuropein in the treatment of osteoporosis by measuring the expression of OPG/RANKL mRNA in osteoblasts. Methods The expression of OPG/RANKL mRNA was detected using fluorescence quantitative PCR ( RT-PCR ) in osteoblasts in the present of different solubility and different time of oleuropein.Results Compared to the control group, the result of RT-PCR showed that oleuropein at all concentrations promoted the expression of OPG mRNA and inhibited the expression of RANKL mRNA.Conclusion Oleuropein may inhibit the secretion of RANKL to reduce the activity of osteoclasts, and promote secretion of OPG in osteoblasts, which combined with R-ANKL that indirectly affects osteoclasts, leading to a decrease of osteoclast activity, and reaching to the purpose of the treatment of osteoporosis.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2015年第5期599-602,共4页 Chinese Journal of Osteoporosis
基金 军区医学科技创新课题(11MA111)
关键词 橄榄苦苷 成骨细胞 增殖 影响 Oleuropein Osteoblasts OPG/RANKL mRNA Influence
  • 相关文献

参考文献14

  • 1American Cancer Society. Cancer facts & figures 2011. Atlanta:American Cancer Society, 2011,2 ( 3 ) :453-457.
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011,61 (2) :69-90.
  • 3Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. 1994 WHO technical Report Series No. 843, Geneva: WHO, 1994, 12 (4) :129.
  • 4Lean JM, Davies, Fuller K, et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest,2003, 112(6) :915-923.
  • 5Lozo P, Krpan D, Krvavica A, et al. Bone histology in postmenopausal osteoporosis-variations in cellular activity. Act M ed Croatica, 2004,58 ( 1 ) : 5 -11.
  • 6Caroline Puel, Jacinthe Mathey, Apostolis Agalias, et al. Dose- response study of effect of oleuropein,an olive oil polyphenol, in an ovariectomy/inflammation experimental model of bone loss in the rat. Clinical Nutrition, 2006, 25, 859-868.
  • 7Carrera-Gonzalez MP. Protective role of oleuropein and its metabolite hydroxytyrosol on cancer. Trends in Food Science & Technology, 2013,31 (2) : 92-99.
  • 8Granados-Principal S, Quiles JL, Ramirez-Tortosa CL, et al. Hydroxytyrosol: from laboratory investigations to future clinical trials. Nutrition Reviews, 2010,68 (2) : 191-206.
  • 9Mohagheghi F, Bigdeli MR, Rasoulian B, et al. Dietary virgin olive oil reduces blood brain barrier permeability, brain edema, and brain injury in rats subjected to ischemia-reperfusion. Scientific World Journal, 2010,10 ( 3 ) : 1180-1191.
  • 10Jabbar S, Drury J, Fordham JN, et al. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis [ J ]. J Clin pathol,2011,64(4) :354-357.

同被引文献45

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部